2020年7月1日
Evaluation of the Tolerability of Gemcitabine and Cisplatin Combination Chemotherapy with a Small Quantity of Replacement Fluid for Biliary Tract Cancer
YAKUGAKU ZASSHI
- ,
- ,
- ,
- ,
- ,
- ,
- ,
- 巻
- 140
- 号
- 7
- 開始ページ
- 929
- 終了ページ
- 936
- 記述言語
- 日本語
- 掲載種別
- 研究論文(学術雑誌)
- DOI
- 10.1248/yakushi.19-00223
- 出版者・発行元
- Pharmaceutical Society of Japan
Cisplatin therapy induces kidney injury as a side effect. Thus, replacement fluid must be administered to prevent kidney injury. In our hospital, we use a Gemcitabine and Cisplatin combination chemotherapy (GC) at a total volume of approximately 500 mL for biliary tract cancer. We investigated the safety of GC with a small amount of replacement fluid. As a result, no serious adverse events and renal injury occurred that required discontinuation of treatment. The median overall survival time was 260 d (95% confidence interval, 154-367 d). This study suggests that GC with a small amount of replacement fluid could be performed tolerability. But we need to be careful about choosing patients such as patients who can drink 1 L orally and patients who can be treated as outpatients.
- リンク情報
- ID情報
-
- DOI : 10.1248/yakushi.19-00223
- ISSN : 0031-6903
- eISSN : 1347-5231
- PubMed ID : 32612058